2026 Predictions

The Unfolding Future of Health – stepping closer to 5P Medicine

Raul Valin, Fujitsu Research of Europe

For decades, the promise of truly personalized healthcare has remained elusive due to the immense complexity of human biology, especially the ambiguous landscape of individual genetic profiles. However, a significant paradigm shift is underway.

The principles of **5P Medicine** – Predictive, Preventive, Personalized, Participatory and Population-based – are finally becoming achievable through advanced artificial intelligence (AI) and computing power. And 2026 looks set to be a breakthrough year.

1. 5P Medicine in Europe

Europe is taking 5P medicine actions as part of a comprehensive strategy for advancing **Personalized Medicine**, which centers on tailoring healthcare to individual patient characteristics. This approach encompasses, **Predictive** diagnostics to forecast disease risk and treatment response, enabling **Preventive** interventions to avert illness. Crucially, it emphasizes **Participatory** healthcare, empowering patients in their medical decisions, and fosters partnership across various sectors-research, industry, healthcare systems, and policymakers-to collaboratively build **Population** health strategies. European actions include significant research funding (e.g., Horizon Europe, the European research programs in healthcare), the development of interoperable data infrastructures such as the European Health Data Space, the integration of personalized medicine into national healthcare systems, and robust engagement with ethical and regulatory frameworks to ensure the responsible and effective implementation of these initiatives across the continent. In 2026, we will see the kick-off of the latest Horizon Europe Cluster 1 projects, where artificial intelligence (AI) is expected to underpin the realization of 5P medicine.

The European strategy in 5P medicine targets several major diseases and conditions. A main focus is cancer, where personalized medicine transforms treatment by using genomic profiling of tumors to direct targeted therapies, immunotherapies, and chemotherapy, moving beyond traditional one-size-fits-all methods. Rare diseases also stand out as a key area, as their diagnostic journey and treatment challenges often greatly benefit from genomic sequencing and personalized therapeutic approaches. Additionally, neurodegenerative diseases like Alzheimer's and Parkinson's, along with other complex chronic conditions such as diabetes and cardiovascular diseases, are increasingly addressed with personalized and predictive strategies aimed at early detection, customized management, and ultimately, preventing disease progression.

The Genomic and Precision Medicine strategy in Spain is an example of the implementation of 5P medicine in Europe. This strategic plan intends to integrate genomic medicine into the

Spanish National Health System, moving towards a more personalized, predictive, preventive, and participatory healthcare model. The Integrated System of Genomic and Precision Medicine, SIGENEs, is the cornerstone of Spain's National Precision Medicine Plan, acting as a unified national platform for genomic data and precision healthcare. It aims to integrate a secure, interoperable infrastructure that not only collects and stores vast amounts of genomic data from patients across Spain but also actively links this information with clinical records, enabling sophisticated bioinformatics and AI tools for interpretation. In 2026, we will see the implementation of SIGENEs, where AI will again play a fundamental role in interpreting genetic variants.

2. AI Expected to Revolutionize Genetic Variant Classification

Around 40% of genetic variants are still classified as "variants of uncertain significance" (VUS) [1], creating a critical bottleneck in clinical interpretation. New AI technologies are addressing this by analyzing multiple genetic databases simultaneously, while crucially integrating automatically generated, explainable text that adheres to clinical guidelines. This supports making AI interpretations to be both accurate and compliant, while fostering trust and accelerating adoption.

By 2026, these breakthroughs are expected to significantly advance 5P Medicine, revealing individual health secrets, empowering clinicians with clearer patient insights, and enabling increased patient participation. AI systems may assist VUS variant interpretation in defined disease categories; accuracy and clinical impact continue to be evaluated in ongoing research. These systems can integrate information from numerous genetic databases simultaneously, creating knowledge graphs that uncover hidden relationships among genetic variants, phenotypes, and disease outcomes.

The breakthrough is in explainable AI that can deliver clinically compliant reports instead of black-box predictions. Healthcare professionals will be able to receive detailed explanations that highlight specific genetic factors, population data, and functional predictions to guide each classification. This transparency might be a key factor in accelerating clinical adoption while maintaining compliance with stringent medical standards.

The impact: AI is expected to help automate the process of genetic reanalysis, allowing genetic counselors to reduce the time required for genetic diagnosis and provide patients with meaningful guidance, rather than dealing with unclear results. Risk assessment for hereditary cancers, diagnosis of rare genetic conditions, and pharmacogenomics is an area of active research; AI-based approaches are being evaluated for their potential to improve predictive healthcare interventions.

3. The Role of Multimodal AI in Transforming Precision Medicine

In 2026, healthcare institutions will progressively test systems that analyze multiple clinical data sources, such as histopathology images, RNA sequencing, copy number variations, or text from clinical records, simultaneously to create integrated AI predictive models.

Early evaluations of multimodal AI predictive models in research settings suggest potential for improved performance in clinical data integration and cancer subtyping; further clinical validation is ongoing. Multimodal AI models are being explored for their ability to analyze

genetic and morphological data, which may contribute to understanding treatment responses and resistance mechanisms; research is ongoing.

Survival prediction models are under investigation for potential individualized forecasting, which will require validation and regulatory review. This technology is expected to be expanded to multiple diseases, including cardiovascular disease, neurological disorders, and autoimmune conditions, marking a shift from single-biomarker tests to comprehensive biological profiling.

4. Natural Language Processing to Unlock Clinical Data Repositories

Advanced natural language processing (NLP) are expected to revolutionize the organization of large collections of unstructured clinical text into searchable phenotype databases. AI systems will be used to automatically identify symptoms, disease patterns, and treatment responses from clinical narratives, connecting them to standardized ontologies, such as the Human Phenotype Ontology codes.

These systems will be able to understand clinical context and nuance, distinguishing between absent and present symptoms, recognizing temporal relationships, and identifying causal links. This will enable retrospective phenotype studies on an unprecedented scale, allowing researchers to analyze millions of clinical records to discover rare disease patterns and signals of treatment effectiveness that are impossible to detect through traditional studies.

The expected result: faster research into rare diseases and the discovery of new therapeutic targets through the analysis of real-world evidence.

5. AI as a Key Factor to Empower Patient Participation

AI-based systems may provide patients and clinicians with personalized health insights and accessible reports that support shared decision-making; any recommendations should be interpreted and personalized by qualified healthcare professionals.

These systems aim to go beyond simple risk scores to explain how specific genetic variants interact with environmental factors, medications, and lifestyle choices. In chronic disease management, AI algorithms are being developed to support the monitoring of patient data and to offer data-driven insights; real-time clinical guidance should constantly be reviewed and tailored by health professionals.

Crucially, these systems are planned for fostering trust and supporting informed patient decision-making by being transparent about uncertainty and limitations.

6. Prospect of Truly Individualized Prevention

The preventive medicine approach is expected to move from focusing on populations to tailored prevention plans driven by AI. Advanced risk models can be used to analyze genetic makeup, lifestyle, environmental factors, and real-time biomarkers to develop customized protocols.

AI-driven risk models aim to advance early identification of at-risk individuals and optimize screening strategies; their effectiveness and clinical use are subject to ongoing study and regulatory approval. Beyond genetics, they will include continuous monitoring data from wearables and environmental sensors to detect subtle pre-disease patterns.

Most importantly, prevention strategies may be adjusted based on individual response patterns, suggesting alternative approaches when interventions are not effective for certain patients.

Conclusion: The 2026 Healthcare Transformation

By 2026, the integration of advanced variant classification, multimodal diagnostics, automated phenotype extraction, patient-empowering AI, and personalized prevention is expected to develop a healthcare ecosystem that fully embodies the principles of 5P Medicine.

We are transitioning from an era where genetic information raised more questions than answers to one where AI provides clear, actionable insights, empowering both clinicians and patients. Advances in personalized healthcare offer the potential to transform how diseases are predicted, prevented, and treated, contingent upon further real-world evidence, validation, and compliance with medical regulations.

The future of healthcare involves transforming data into insights that enhance human health and quality of life. As we near 2026, that future is more attainable than ever.

[1] Source: https://doi.org/10.1093/nargab/lqae154

Disclaimer: This content is informational and is not intended as medical advice, diagnosis or treatment guidance; individuals must consult qualified professionals for clinical decisions and to receive medical diagnostics, advice or treatment. This content does not contain any recommendations regarding the use of specific medical devices, medicines or remedies, or the application of specific treatment methods. Regulatory requirements, including usage of AI, differ by country; any tools or methods described must be evaluated and used in accordance with European and local laws, regulation, guidance, and approvals. Any forward-looking statements reflect current expectations and are subject to validation, regulatory review, and change as evidence evolves.

Raul Valin
Fujitsu Research of Europe

Raul Valin has 10 years of experience in Fujitsu Research of Europe, working on business support, research and innovation. Currently, he is the Project Director of the Genomics AI project. A global project to transform healthcare by using Fujitsu innovations in artificial intelligence and computing.